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High-dose fractionated total lymphoid irradiation (TLI), a radiotherapy technique 
used for human lymphomas, allows for the engraftment of completely allogeneic bone 
marrow (BM) without clinical graft vs. host disease (GVHD) in adult inbred rodents 
and outbred dogs (1-5). TLI-treated BALB/c (H-2  a) mice given 30 ×  106 C57BL/Ka 
(H-2  b) BM cells developed stable mixed chimerism in the blood and lymphoid tissues 
and specific tolerance to C57BL/Ka skin grafts. Donor-type (H-2  b) cells comprised 
60-90%  of peripheral  blood  lymphocytes (PBL)  and  ~90%  of splenocytes  in  the 
chimeras  (1).  C57BL/Ka ~  BALB/c chimeras  prepared  with  TLI  developed  no 
clinical signs of GVHD and routinely survived >100 d.  In contrast, BALB/c mice 
given lethal whole-body irradiation and  30  ×  106  C57BL/Ka BM cells developed 
typical GVHD resulting in 60% mortality at 1.5 d and 9.5% mortality at 60 d after BM 
transfer (2). 
Previous studies (6) showed that the injection of C57BL/Ka ---* BALB/c chimeric 
spleen cells into lightly irradiated  (550  rad)  BALB/c mice did not lead to GVHD 
even though 90% of the cells were of donor (C57BL/Ka) origin. These sublethally 
irradiated recipients, in turn, became stable mixed chimeras and accepted C57BL/ 
Ka skin grafts (6). Injection of chimeric cells into third-party hosts was not attempted. 
The  absence  of GVHD  in  the  mature  TLI  chimeras  and  in  irradiated  BALB/c 
recipients  of chimeric  spleen  cells  had  a  number  of possible  explanations.  These 
included clonal deletion, active suppression by donor and/or host cells, blocking by 
serum factors, or general immunodeficiency of donor-type cells maturing in a  com- 
pletely allogeneic thymic microenvironment. A possible role for host suppressor cells 
was suggested by studies in which spleen cells from BALB/c mice given TLI without 
BM  were  found to  exert  a  potent  suppressor  effect on  mixed  leukocyte reactions 
(MLR)  regardless of the identity of the responder  and stimulator cells  (7).  When 
injected along with C57BL/Ka BM, these suppressor cells protected the majority of 
lethally irradiated BALB/c mice from acute GVHD. t 
In this work, we used a GVHD mortality assay to study the mechanism of the graft 
vs.  host tolerance in the completely allogeneic mixed chimeras prepared with TLI. 
The  results  indicate  that  donor-type  (C57BL/Ka)  lymphocytes in  long-term  TLI 
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chimeras are specifically tolerant to the tissues of the host. Thus, lack of GVHD  is not 
dependent upon the continued presence of suppressor cells of host (BALB/c) origin or 
on chronic immunodeficiency of the donor-type cells. 
Materials  and Methods 
Chimeras.  BALB/c (H-2  a) mice, 4-6-mo old, were given TLI in 17 fractions of 200 rad each 
as described previously (1).  1 d later, BM cells (30 ×  10  n) from C57BL/Ka (H-2  b) donors were 
infused via the lateral tail vein. Chimerism of the PBL of individual BM recipients was assayed 
at  least  40 d  after transplantation  by a  complement  (C')-dependent  microcytotoxicity assay 
using BALB/c anti-C57BL/Ka antiserum (1). 
Adoptive Transfer Recipients.  Adult (3- to 6-too old) male and female BALB/c and C3H (H- 
2  k) mice were used as whole-body irradiated  (WBI) recipients of chimeric and normal spleen 
cells in GVHD mortality experiments. WBI was delivered using a 250-kV,  15-mA Philips unit 
(Philips Electronic Instruments, Inc., Mahwah, N. J.) at a dose rate of 93 rad/min. Neomycin 
sulfate (500 #g/ml) and polymyxin B (100 #g/ml) were added to drinking water before WBI 
and continued indefinitely. 
Isolation of Chimeric Spleen Cells of Donor (C57BL/Ka)  Origin.  Four  to six  C57BL/Ka 
BALB/c chimeras  (>100 d  after transplantation)  were used for each experiment.  Single-cell 
suspensions were prepared in cold RPMI-1640 medium (Grand Island Biological Co., Grand 
Island, N. Y.). The cells were spun at 250 g and resuspended at  10 X  10S/ml  in RPMI-1640 
medium that contained 0.3% bovine serum albumin  (Sigma Chemical Co., St.  Louis, Mo.). 
C57BL/Ka anti-BALB/c alloantiserum was added to a final concentration of 1:50 for 30 min 
at 37°C. After spinning at 250 g for 10 rain at room temperature, the unbound antiserum was 
removed. The cells  were resuspended  (20  X  10e/ml)  in rabbit  C'  (1:8)  (Lo-Tox; Cedarlane 
Medical Laboratories Ltd., Ontario, Canada) at 37°C for 45 min and then spun for 10 min at 
250  g.  The  cells  were  washed  two  times  in  fresh  medium,  counted,  and  adjusted  to  the 
appropriate concentration in RPMI-1640. In preliminary experiments with antiserum concen- 
trations of 1:100 or greater, this procedure resulted in 90-100% cytotoxicity for BALB/c spleen 
cells and <5% cytotoxicity for normal C57BL/Ka spleen cells. 
Results  and  Discussion 
BM Transplantation without  GVHD in Mice after  TLI.  More  than  90%  of BALB/c 
mice  given  TLI  followed  1 d  later  by C57BL/Ka  BM  cells  (25  ×  106) developed 
stable mixed chimerism. Cytotoxieity assays were performed on PBL from individual 
mice at least 40 d after BM transfer.  PBL from chimeric recipients contained 50-90% 
donor-type  (H-2  b)  cells.  C57BL/Ka  skin  grafts  survived  indefinitely  on  chimeric 
animals.  None of the marrow recipients showed clinical signs of GVHD. Spleen cells 
obtained  from  chimeras  >100  d  after  BM  transplantation  were  used  for  all  cell 
transfer experiments. 
Specific Absence of G VHD in Mice Given Sublethal WBI and Chimeric Spleen Cells.  9 of 
10 BALB/c mice given 450 rad WBI followed 24 h  later by an intravenous infusion 
of chimeric spleen cells  (25 ×  106-50 ×  106) survived >45 d  with no signs of GHVD 
(Table  I). BALB/c recipients  given 450 rad and normal C57BL/Ka spleen  cells  (25 
×  10  n) developed characteristic signs of acute GVHD  (diarrhea,  weight loss). Only  1 
of 10 survived > 15 d. All of 9 BALB/c mice given 550 rad WBI and chimeric spleen 
cells  (25 ×  10  ~) survived >45 d, whereas none of 22 similarly irradiated  recipients of 
normal  C57BL/Ka spleen  cells  (25  ×  10  ~)  survived >15  d.  Donor-type  (H-2  b)  cells 
were present  in the PBL of two of nine recipients of chimeric spleen cells when tested 
at least 40 d  after transfer. 
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TABLE I 
Survival of Mice Given Sublethal WBI and Chimeric Spleen Cells 
Fraction surviving  No. chi- 
Recipient  Strain  Spleen cell .source  meras/No. 
treatment 
15 d  30 d  45 d  tested* 
tad 
BALB/e  450  None  10/I 0  9/10  9/10 
BALB/c  450  G57BL/Ka  1/10  0/10  --  NT 
(25 x l0  s) 
BA  LB/c  450  Chimera  t 0/10  10/10  9/10  0/9 
(25  50 x  Jo  s) 
BALB/c  500-550  None  37/47  37/47  37/47 
BALB/c  500-550  C57BL/Ka  0/22  --  --  NT 
(25 x  1o") 
BALB/c  500-550  Chimera  9/9  9/9  9/9  2/9 
(25 ×  106) 
G3H  650  None  40/44  39/44  38/44 
C3H  650  G57BL/Ka  0/26  --  --  NT 
(25 x  lo  ~) 
C3H  650  Chimera  3/5  0/5  --  NT 
(25 x  10") 
NT, not tested. 
* Fraction of animals with _>16% donor-type  (G57BL/Ka)  PBL at  least 40 d  after cell transfer. 
chimeras, third-party mice of the C3H strain (H-2  k) were treated with sublethal WBI 
(650 rad) and given 25 ×  106 chimeric spleen cells intravenously. G3H recipients were 
treated with a higher radiation dose to achieve a similar radiation mortality to that 
observed with BALB/c mice given 500-550 rad WBI (Table I). None of five survived 
>30  d  after cell transfer.  38 of 44 mice given radiation alone survived >45  d, but 
none of 26 given WBI  and  normal  G57BL/Ka spleen cells survived >15  d.  These 
experiments suggested, but did not prove, that the donor-type cells in chimeric spleen 
were both immunocompetent and specifically tolerant to host tissues. The possibility 
remained that the GVHD observed in third-party mice was mediated by cells of host 
origin  (~20%  of the  chimeric  spleen  cells),  and  that  lack  of GVHD  in  BALB/c 
recipients was mediated by suppressor cells of host origin. These alternative expla- 
nations  pointed  to  the  need  to  assess  the  graft  vs.  host  reactivity  of an  isolated 
population of chimeric donor-types cells. 
Specific Absence of GVHD Potential  of Donor-Type  (H-2  b)  Chimera Spleen  Cells.  We 
isolated donor-type (C57BL/Ka) spleen cells from C57BL/Ka ~  BALB/e chimeras 
>100 d after BM transplantation. Pooled spleen cells (~80% C57BL/Ka) were treated 
in vitro with C57BL/Ka anti-BALB/c alloantiserum (anti-BALB/c) and rabbit C' to 
eliminate cells of host (BALB/c) origin. The remaining cells were washed, and aliquots 
that  contained  25  ×  106  viable  cells  were  injected  intravenously  into  sublethally 
irradiated  BALB/c and  third-party  (C3H)  hosts  (Table II).  Data  in  Table II was 
pooled from at least  two experiments of each type.  17 of 20  BALB/c recipients of 
chimeric donor-type spleen cells survived in apparent good health for >60 d after cell 
transfer. In contrast, irradiated G3H recipients of the same cells developed a severe 
wasting syndrome. 2 of 12 survived >15 days, and none >30 d. 85% of mice given 
radiation alone survived >60 d. The mortality of C3H mice given WBI and normal 
C57BL/Ka spleen cells was  100% at  15 d. The results show that cells of donor origin 
in the chimeras have lost their reactivity to the tissues of the host strain even when 
removed from the chimeric environment, but can  mediate GVHD against  a  third- 
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TABLE II 
Survival and Chimerism of Mice Given WBI and Chimeric Spleen Cells 
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Strain 
Fraction surviving  No. chi- 
Recipient  Spleen cell source  meras/No. 
treatment  15  30  45  60  tested* 
tad 
BALB/c  500-550  None  37/47  37/47  37/47  37/47 
BALB/c  500-550  C57BL/Ka (25 x  10  e)  0/22  --  --  --  NT 
BALB/c  500-550  C57BL/Ka  (20  X  l0  s)  +  BALB/c  (20  X  11/14  11/14  11/14  11/14  0/6 
10  a) 
BALB/c  500-550  C57BL/Ka (20 ×  108) +  BALB/c (20 ×  l0  s  0/12  --  --  --  NT 
anti-BALB/c treated):[: 
BALB/c  500-550  Chimera (25 ×  l0  s anti-BALB/c treated):~  17/20  17/20  17/20  17/20  9/20~ 
C3H  650  None  40/44  39/44  38/44  38/44 
C3H  650  C57BL/Ka (25 ×  l0  s)  0/26  --  --  --  NT 
C3H  650  Chimera (25 ×  106 anti-BALB/c treated)~  2/12  0/12  --  --  NT 
NT, not tested. 
* Fraction of animals with >'16% donor-type (C57BL/Ka) PBL at least 40 d after cell transfer. 
:~ Cells were pooled and treated in vitro with aoti-BALB/c antiserum and C'. 
§ Mean of individual values of definite chimeras was 44% donor-type cells. 
None of 22 BALB/c mice given sublethal WBI and normal G57BL/Ka spleen cells 
survived >15 d. However, cotransfer of normal BALB/c spleen cells (20 ×  106) with 
the C57BL/Ka spleen cells (20 ×  106) protected the majority of irradiated BALB/c 
recipients from GVHD.  11 of 14 survived >60 d  (Table II). The syngeneic inoculum 
presumably  leads  to  rejection  of the  allogeneic  cells  because  chimerism  was  not 
produced. However, treatment of the spleen cell mixture with anti-BALB/c antiserum 
and C' eliminated the protective effect, because none of 12 survived > 15 d. This result 
provided further evidence that the cytotoxicity method used in these studies elimi- 
nated host-type (BALB/c) cells, but allowed donor-type cells to mediate GVHD. 
Development  of Chimerism  in  Irradiated  BALB/c  Recipients  Given Donor-Type  (H-2  b) 
Chimeric or FI Hybrid Spleen Cells.  9 of 20 irradiated BALB/c mice (500-550 rad) given 
donor-type cells  (25  ×  106) from long-term TLI chimeras  developed stable  mixed 
chimerism (Table II). The PBL of the adoptive recipients contained a  mean of 44% 
donor-type cells when tested at least 40 d after cell transfer. The infusion of untreated 
chimeric spleen cells led to stable chimerism in only 2 of 9 BALB/c recipients given 
500-550  rad WBI and in none of the recipients given 450 rad  (Table I). The data 
suggest that rejection of allogeneic cells by the lightly irradiated hosts may account 
for the failure to achieve uniform chimerism. The more effective transfer ofchimerism 
with isolated chimeric donor-type cells suggests the possibility that  host-type cells 
have a proliferative advantage in recipients of unfractionated spleen cells. 
The transfer of tolerance with chimeric donor spleen cells could have been mediated 
by suppressor  cells of donor origin,  or  alternatively, by  donor  antigens acting as 
tolerogens. The latter mechanism is more likely, because the majority of BALB/e mice 
given 500-550 rad WBI and (BALB/c ×  C57BL/Ka)F1 spleen or BM cells (60 ×  106) 
developed high levels of stable chimerism (Table III), and accepted C57BL/Ka but 
not  C3H  skin  grafts  indefinitely  (M.  Gottlieb,  S.  Strober,  and  H.  S.  Kaplan. 
Unpublished  observations.).  It  would  appear  that  in  this  strain  combination,  the 
injection of cell populations that cannot mediate a  graft vs. host reaction (i.e., Fa or 
donor-type chimeric spleen cells)  produces stable mixed chimerism and tolerance in 
recipients given sublethal WBI. 
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TABLE III 
Chimerism of BALB/c Mice Given Subhthal  WBI and (BALB/c  X 
C57BL/Ka)F1 Spleen or BM Cells 
No. chimeras/  Mean per- 
Recipient treatment  Cell source  No. mice  centage of 
tested*  chimerism:~ 
tad 
450  Fl spleen (60 X  10  s)  0/11  -- 
500-550  Fi spleen (60 X  10  e)  27/29  67 
500-550  F~ BM (60 ×  l0  s)  4/4  55 
* Fraction of animals with __.16% donor-type (C57BL/Ka) PBL at least 40 d  after cell 
transfer. 
Mean of individual values of definite chimeras. 
mice and rats prepared with lethal WBI or cyclophosphamide. These chimeras have 
been constructed in F1 hybrids by infusion of parental  BM cells treated with anti- 
Thy-1  antiserum and C', or in completely allogeneic combinations by selection of 
donor-recipient strains where a  substantial proportion of recipients survive GVHD 
(8-11). Lymphocytes from lethally irradiated F1 hybrid recipients of treated BM from 
one parent proliferate in response to cells of the other parent in vitro (MLR), but do 
not produce specific cell-mediated lympholysis (CML)  (8).  Suppressor  cells of the 
CML could not be demonstrated, suggesting that the clone of cytotoxic lymphocytes 
responsive to the host tissues had been deleted. However, studies in fully allogeneic 
r.at chimeras that survive transient GVHD suggest that suppressor cells maintain the 
tolerant state (11). Multiple mechanisms may be operative in these instances of graft 
vs. host tolerance as seems to be the case for neonatal tolerance (12). 
Our experiments in progress attempt to determine whether graft vs. host tolerance 
in TLI chimeras is mediated by antigen-specific suppressor T  cells of donor origin or 
by deletion of specific host-reactive lymphocyte clones. An ongoing role for serum 
blocking factors in chimeras is less likely because washed donor-type spleen cells in 
the  absence  of chimeric  serum  led  to  sustained  chimerism  without  GVHD  in 
BALB/c mice given sublethal WBI. 
Summary 
BALB/c mice given allogeneic (C57BL/Ka) bone marrow cells after total lymphoid 
irradiation become stable chimeras with ~80% donor-type and 20% host-type cells in 
the spleen. The chimeras do not develop graft vs. host disease (GVHD). Purified cells 
of C57BL/Ka origin from the chimeras mediated GVHD in lightly irradiated C3H 
(third party), but not in BALB/c (host-strain) mice. Thus graft vs. host tolerance in 
the chimeras could not be explained by complete immunodeficiency of donor-type 
cells,  serum  blocking  factors, or  suppressor  cells of host  (BALB/c)  origin.  Clonal 
deletion or  suppression  of lymphocytes reactive  with  host  tissues  remain  possible 
explanations. The transfer of donor-type chimeric spleen cells to BALB/c recipients 
given  500-550  rad whole-body irradiation WBI  led  to stable  mixed chimerism in 
~50% of recipients. The cells were presumably acting as tolerogens because similarly 
irradiated  BALB/c mice given  (BALB/c ×  C57BL/Ka)F1 spleen or bone marrow 
cells also became stable mixed chimeras. GOTTLIEB ET AL.  BRIEF DEFINITIVE REPORT  741 
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